NEW YORK (Reuters Health) - New research suggests that the cholesterol-lowering ability of “statin” drugs, like Lipitor and Mevacor, is blunted when the blood contains high levels of an enzyme called phospholipid transferprotein.
NEW YORK (Reuters Health) - New research suggests that the cholesterol-lowering ability of “statin” drugs, like Lipitor and Mevacor, is blunted when the blood contains high levels of an enzyme called phospholipid transferprotein.
